Principal Investigator: Michael R. Rickels, MD, MS
Title: A Randomized, Controlled Trial Comparing the Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß –Cell Mass in Patients with Impaired Fasting Glucose or Early Type 2 Diabetes
Sponsor: Center for Excellence in Regenerative Medicine, PA State Department of Health
Description: One of the causes of an increase in blood sugar is a decrease in the amount of cells that produce insulin. Recent research shows that a hormone (GLP-1) may increase the numbers of these cells or help them to work better. Exenatide is a drug that works like GLP-1 and sitagliptin is a drug that causes your body to produce more GLP-1. Exenatide and sitagliptin may help insulin cells make more insulin. Glimepiride is another treatment for increased blood sugar that leads to a release of insulin, but is not expected to increase how much insulin is made.
The purpose of this study is to see if exenatide and sitagliptin increase the amount of insulin made by the pancreas more than glimepiride. Exenatide (Byetta®), sitagliptin (Januvia®), and glimepiride (Amaryl®) are all approved by the United States Food and Drug Administration (FDA) to treat high blood sugar.
This research study participation would last between 6-8 months and would involve 8 visits to the Hospital of the University of Pennsylvania campus.
Eligibility: You may be eligible to participate if you have type 2 diabetes or prediabetes, which means your blood sugar is only a little high. You must be between 18 and 70 years of age and not be taking insulin or more than two medications for diabetes.
Compensation: $600 paid at the end of participation, $10 cash per visit for transportation
For more information or if you may be interested in participating, please contact:
Name: Armando León